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Summary
The basis of antiviral protection by memory cytotoxic T lymphocytes (CTL) was investigated
in vivo and in vitro using lymphocytic choriomeningitis virus (LCMV) and recombinant vaccinia
viruses expressing the LCMVglycoprotein (vacc-GP) or -nucleoprotein (vacc-NP) . The widely
replicating LCMV with a tendency to persist induced solid long-term protective memory . The
poorly replicating vaccinia recombinant viruses revealed in the vaccinated host that the antiviral
capacity of the secondary immune T cell response and the protection against lethal LCM was
dependent upon the immunizing antigen and its dose. Protection against lethal choriomeningitis
is less sensitive to assess memory because it depends upon high levels of CTL precursors (p)
and/or on an activated state of memory CTL . In contrast, antiviral protection measured as the
capacity of the primed host to reduce virus titers after challenge infection correlated with elevated
CTLp frequencies after immunization with liveLCMV or recombinant vaccinia virus expressing
the major LCMV epitope . CTLp frequencies were constantly increased up to 70 d for LCMV
immune mice, but rapidly decreased a few weeks after immunization with low dose vaccinia
recombinant virus. For example, mice primed with 2 x 106 plaque-forming units (PFU) of
vacc-NP, or 2 x 102 PFU, or 2 x 106 PFU of vacc-GP were antivirally protected on day 7
but not after day 30 when CTLp could not be measured any longer in vitro. However, greater
priming doses of vacc-NP (104 or 2 x 10 6 PFU) as well as LCMV (2 x 10 2 PFU) induced
elevated levels ofCTLp and antiviral protection for 60 d or longer. Adoptive transfer experiments
ofimmune spleen cells into syngeneic recipients without addition of antigen demonstrated that
maintenance of the antiviral protective capacity of the transferred cells depended on the presence
of viral antigen . Thus, antiviral protection by memory CTL may be rather short-lived since it
is based on activated T cells continuously stimulated by persisting antigen. This is best achieved
by high immunizing antigen doses yielded either by widely replicating viruses or high doses
of poorly replicating recombinant vaccines .
mmunological memory is one of the key characteristics of
the immune system, and evidence forT orB cell memory
has been collected for many years (for reviews see references
1-3) . Although immunological memory as defined opera-
tionally has been studied widely, there is relatively littleknown
about the molecular and cellular basis of this phenomenon .
Its nature has been explained in several ways . First, memory
may reflect either numerically increased precursor frequen-
cies (4) or second, a qualitatively altered differentiation state
of memory T or B cells as compared with naive cells (5-9) .
Third, memory may simply represent repeated restimulation
by crossreactive environmental antigens (3, 10) or antigen
persistence that continuously drives T or B cell responses
(11-14) . These three mechanisms may all apply.
Studies on antigen persistence and its role in maintaining
memory have revealed an important role ofantigen-antibody
complexes on follicular dendritic cells forB cell memory (11,
14) . Older studies showing that T cellmemorymay be short-
lived (15-19) have recently been corroborated by transfer studies
using the cytotoxic T cell response to the maleH-Y antigen
or Th cell function specific for a carrier protein . This study
implied a role for antigen persistence in the maintenance of
T cell memory (20) .
Immunological memory is the basis for vaccines against
infectious agents or their toxins . The question of whether
antigen persistence or other factors maintain memoryT cells
is therefore not only ofgreat interest in general, but also rele-
vant to the rational design of vaccines . The experiments
presented here were aimed at analyzing the basis of antiviral
protective cytotoxic T cell memory in mice using lympho-
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protection against acute infection with LCMV are almost ex-
clusively dependent on virus-specific CTLs (21, 22) . Nor-
mally, antibodies do not play a major role (23, 24) in this
process. Also, protection against immunopathologically medi-
ated lethal LCM induced by intracerebral infection (25, 26)
is usually strictlyCTLdependent. There exists a clear corre-
lation between immunizing LCMV antigen, mouse H-2
MHChaplotype, and the capacity of mice to generate LCMV
specific CTLs mediating protection from LCM (27, 28) . For
BALB/c (H-2d) mice, nucleoprotein (NP) (aa118-132) is the
majorCTL target, whereasglycoprotein (GP)-specific CTLs
are found only at low frequencies (28-30) . CTL memory to
viruses includingLCMV hasbeen analyzed by several groups
(31-35), butthepotential role of persisting antigen, (24, 36)
has not been formally analyzed as yet .
The experiments presented here were aimed at assessing
protective memory in the vaccinated host itself and comparing
it with memory analyzed in vitro or in adoptive transfer ex-
periments . We had argued before (37) and presented some
evidence (17) indicating that virus-specific crossreactiveT help
may be very short-lived in the vaccinated host, which might
explain why primed crossreactiveT help may not be able to
improve antibody responses to new virus variants.
This study therefore compared in the vaccinated host in
vivo the protective capacity and duration of T cell memory
with the induction and maintenance of elevated CTLp fre-
quencies after infection of mice with either well-replicating
LCMV or the poorly replicating recombinant vaccinia viruses
(38-40) expressing theLCMVglycoprotein (vacc-GP) or the
LCMVnucleoprotein (vacc-NP) (28, 41) . Since in contrast
to LCMV, vaccinia virus replicates only to a rather limited
extent in adult mice (42), the latter virus permitted an ap-
proximate titration of the vaccine . In fact, after the intrave-
nous infection of mice with 2 x 106 PFU of the tyrosine
kinase negative variant, we have not been able to isolate de-
tectable (>10 3 PFU/g organ) virus from any of the organs
tested . The limited antigen reservoir initially provided by the
immunizing recombinant vaccinia viruses may therefore be
expected to decline over time and drop below levels neces-
sary for maintenance of protective T cell memory. This is
not readily seen in LCMVimmune mice sinceeven low doses
ofLCMV are shown to replicate to very high titers and since
despite efficient elimination, LCMV hasbeen shown to often
persist in mice (23, 24, 36, 43, 44) .
The experiments here show that depending upon the de-
tection assay used, antivirally protective memory T cells as-
sessed in vivo correlated with CTLp detected by limiting di-
lution assays in vitro. Under conditions wheretheimmunizing
antigen seemed limited, protective memory T cells declined
rapidly within afew weeks. Thus, long-term antivirally pro-
tective T cell memory against LCMV in a vaccinated host
itself seems to be driven by persisting antigen . This conclu-
sion was supportedby adoptive transfer experiments showing
1 Abbreviations used in this paper: GP, glycoprotein; LCMV, lymphocytic
choriomeningitis virus; NP, nucleoprotein ; p, precursor.
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that in the absenceofantigenic restimulation, antivirally pro-
tective T cell memory declined rapidly within a week .
Materials and Methods
Mice. BALB/c (H-2d) were purchased from the Institut fur
Zuchthygiene (Zurich, Switzerland) . Mice were immunized intra-
venously by injecting 200 PFU of theLCMV WE isolate . Immu-
nizations with recombinant vaccinia viruses (vacc-NP, vacc-GP) were
given intravenously with the virus doses indicated in the separate
experiments.
Viruses.
￿
TheLCMV WE isolate (24) was used in this study.
Recombinant vaccinia virus expressing theLCMVGP (vacc-GP)
was a gift from D . Bishop, Oxford University. The LCMVNP
recombinant vaccinia virus (vacc-NP) has been described in detail
earlier (28, 38, 39, 45) .
Viral Titers .
￿
Four mice per group immunized with the indi-
cated virus doses were challenged intravenously with 200 PFU of
LCMVWE after various time intervals . 3d later, theLCMV titers
in the spleens were measured in a plaque assay (46) . Control mice
were primed with vaccinia virus (2 x 106 PFU) not expressing
LCMV antigens.
Protection against LethalLCM.
￿
Four to five mice per experimental
groupwere challenged intracerebrally after different time intervals
with a lethal dose (either 10" or 102 PFU in 30 /Al) ofLCMV WE .
The incidence of lethal LCM was registered over a time period of
3 wk and themean time to death ± SEM ofeach group was cal-
culated .
Protective Capacity ofImmune Spleen Cells.
￿
Mice immunized at
various time points with 100 PFUofLCMV WE or the indicated
vacc-NP doses served as donors forimmune spleen cells . Single spleen
cell suspensions were prepared and the indicated numbers of cells
were injected in 0.4 ml balanced salt solution (BSS) into syngeneic
recipients . Some of the recipients were infected intravenously with
100 PFU of LCMV WE 1 d before adoptive transfer to permit
virus to replicate and viral antigen to be expressed . Others were
infected at various time points after the transfer of immune lym-
phocytes. To test the protective capacity of the transferred spleen
cells, the virus titers in the recipients' spleens were measured on
day 4 after challenge infection, i.e., when the recipients' endoge-
nous LCMVspecific immune response had not yet developed .
Limiting Dilution Assays .
￿
Single spleen cell suspensions from
two to three mice per group were prepared . 10 5 immune spleen
cells per well were placed into 24 wells of a round-bottomed tissue
culture microtiter plate and titrated in eight steps of twofold dilu-
tions . Total spleen cell numbers (3 x 105/well) were held constant
by adding irradiated syngeneic normal spleen cells . After stimula-
tion with 2 x 10" LCMVinfected peritoneal macrophages for 7 d,
each individual culture was tested in a "Cr-release assay on H-2
matched target cells infected with LCMV or left uninfected as con-
trols . The percentages of 24 cultures in one dilution step that were
negative for LCMVspecific cytotoxicity were measured and logarith-
mically plotted against the number of responder cells (see Fig. 2
A). The cutoff to consider a well positive was determined by sub-
jecting vaccinia-immune spleen cells to the same procedure and cal-
culating themean cpm from 24 cultures plus three times the SD .
CTLp were read from the graph at 37% negative wells (47, 48) .
Results
T Cell Memory Assessed by Protection Against Choriomenin-
gitis after Intracerebral Challenge Infection . The influence of
the immunizing dose, the time between immunization and
Cytotoxic T Cell Memory to LCMV Is Governed by Persisting Antigeninfection and the challenge dose on the protective capacity
of vacc-NP and vacc-GP against lethal LCM disease was in-
vestigated in BALB/c (H-2d) mice. These mice generate a
dominant LCMVNP-specific and only a very weak GP-specific
CTL response (28) . Antiviral and immunopathological re-
sponses in both normal mice and mice vaccinated with vacc-GP
or vacc-NP are mediated by cytotoxic CD8+ T cells and not
antibodies as could be shown by treatment with anti-CD8
mAbs (25, 30) . Four to five mice were vaccinated with var-
ious doses of vacc-NP or vacc-GP and challenged intracerebrally
after different time intervals with two doses ofLCMVWE
(Table 1) . The mortality rate and the mean time to death
was then registered .
At a time interval of 10 d between priming and challenge
infection, immunization with the two doses (2 x 106 and
2 x 104 PFU) of vacc-NP protected mice against both
LCMV challenge doses. Vacc-GP-immune mice were never
fully protected against any challenge dose, but 25-40% of
the mice survived the LCMV challenge infection (Table 1) .
Vaccinia virus-immunized control mice all succumbed to le-
thal LCM . A shift of 1-2 d in the mean times to death was
seen in vacc-GP-immune groups, indicating a low level of
immunization causing more rapidly developing im-
munopathology. Similar results were seen 20 d after vaccina-
tion . At a time interval of 100 d between priming and chal-
lenge infection, immunization with 2 x 106 PFU of
vacc-NP could not protect against an LCMV dose of 104
PFU, whereas the same immunizing dose resulted in protec-
tion of80% of the animals that were challenged with a lower
LCMV dose of 10 2 PFU (Table 1, bottom) . It is noteworthy
day 10
LCMV 102
￿
100
Vacc-NP 2 x 10 6
￿
100
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that (except for vacc-GP 2 x 106 PFU day 10 primed mice)
an acceleration by 2-3 d of the average time to death was
observed in high dose challenged mice (i .e ., 5.0 + 0.5 d for
vacc-NP primed mice day 100 vs . 7-8 d in controls), indi-
cating that vaccination did have an accelerating effect on
progression ofdisease even ifit did not protect (Table 1) . Thus,
immunization with low doses and/or less immunogenic vac-
cines resulted in diminished protection that lasted for a shorter
time . Note, however, that antiviral protection is not an abso-
lute readout parameter but also depends upon the LCMV
challenge dose. Accordingly, protection against lower chal-
lenge doses tended to be longer-lasting than against high chal-
lenge doses . Also it must be stated that protection against
lethal LCM depends upon a markedly accelerated immune
responsewhen compared with normal mice, as has been shown
earlier (23, 49) .
Kinetics ofAnti-LCMV Protection Assessed by Virus TiterReduc-
tion . The antivirally protective capacity of vaccinated mice
was analyzed as follows : BALB/c mice were immunized with
various doses of vacc-NP (Fig. 1) and challenged intravenously
with 200 PFU ofLCMV WE after different time intervals .
LCMVimmune mice served as positive controls with optimal
protection, and vaccinia-immune mice as negative controls .
3 d after the challenge infection, LCMV titers were measured
in spleens. The antivirally protective capacity of vaccination
with the two high doses of vacc-NP was extensive, causing
about a 1,000-fold reduction of viral titers, and was com-
parative with LCMVimmune mice when monitored during
a time interval of 56 d (Fig . 1 A) . In contrast, BALB/c mice
immunized with a low dose of vacc-NP (2 x 102 PFU)
Table 1 .
￿
Effects of Virus Vaccine, of Vaccination Dose, and of Time after Vaccination on Susceptibility to LCM
Challenge infection with 102 PFU LCMV
day 20
￿
day 100
100
￿
100
100
￿
80 (7.0 ± 0.5)
Groups of four to five BALB/c mice were primed intravenously with the indicated doses of LCMV and vaccinia viruses on day 0 and challenged
on the given days thereafter with 10^ or 102 PFU of LCMV-WE intracerebrally . Data represents survival after challenge infection. Time to death
was monitored every 12 h and the mean times to death ± SEM are given in parentheses ; percent lethality was determined on day 21 after challenge
infection . All deaths occurred before day 11 .
Priming
infection (PFU) day 10
Challenge infection with 10 4 PFU LCMV
day 20 day 100
/ 05
LCMV (102) 100 100 100
Vacc-NP (2 x 106 ) 100 100 0 (5 .0 ± 0.5)
Vacc-NP (2 x 10') 100 100 ND
Vacc-GP (2 x 106 ) 40 (7 .0 ± 1 .0) 25 (5 .7 ± 0.3) ND
Vacc-GP (2 x 10') 0 (6 .0 ± 0.5) 0 (7 .0 ± 0.5) ND
Vaccinia (2 x 10 6 ) 0 (7 .4 ± 0.4) 0(7.0±0.5) 0(8.0±0.5)w
a
n
7
6
5
4
<3~
6 io 4 '0 6
.
0 0 io ao 6
time between priming andchallenge infection (days)
Figure 1 .
￿
Antiviral protection after immunization with various doses
of vacc-NP (A) or vacc-GP (B) . Four BALB/c (H-2d) mice per group were
immunized intravenously with 2 x 10 6 ￿2 x 104 (-C-), or 2 x
102 PFU (-0-) of vacc-NP and vacc-GP, respectively. Two additional
groups of four mice were immunized with 200 PFU of LCMVWE
(--A-) or 2 x 106 PFU of vaccinia (-*--) as controls . After various time
intervals, the mice were challenged intravenouslywith 100 PFU ofLCMV .
3 d later, the spleens were removed and the virus titers were determined
(46) . The loglo values of virus titers per gram of spleen are indicated .
were protectedwhen challenged 7 d after immunization, but
not at 14 d or later.
Vaccination with various doses of vacc-GP (Fig . 1 B) re-
vealed that immunization with a high dose of vacc-GP in-
duced efficient antiviral protection on day 7 . This protection
decreased with the vaccination dose and with time. No pro-
tection was measured after 56 d as indicated by high virus
titers in mice vaccinated with all immunizing doses of vacc-
GP. Thus, again the immunizing dose and the quality of the
antigen influenced the antiviral protective capacity, depending
upon the time after vaccination .
Analysis ofthe Kinetics ofCytotoxic Anti-LCMV-speck CTLp
Frequencies. There is experimental evidence from several
model systems that immunological memory correlates with
increased CTLp frequencies (1, 4) . Therefore, limiting dilu-
tion assays were performed with spleen cells ofBALB/c mice
immunized with vacc-NP, vacc-GP, wild-type vaccinia virus,
or LCMV WE (Fig . 2 A and see Materials and Methods) .
Priming with 2 x 106 or 2 x 104 PFU of vacc-NP induced
LCMVNP-specific CTLp frequencies decreasing eight- or
threefold, respectively, between day 28 and days 50 or 90 (Fig.
2 B) .
Priming with LCMV resulted in 3-10-fold higher overall
frequencies that did not decline with time ; e.g ., CTLp were
determined on day 170, yielding a frequency of 1:5 x 10 3
for 2 x 102 PFU LCMV primed mice (data not shown) .
Immunization with a low vacc-NP dose (2 x 10 2 PFU) or
a high vacc-GP dose (2 x 106 PFU) did not induce any de-
tectable LCMVspecific CTLp above background levels 30 d
or later after priming. For technical reasons, frequencies of
<1:105 could not be measured reliably (4, 50) . But note that
anti-LCMV protection measurable in vivo after immuniza-
tion with 2 x 102 PFU of vacc-NP on day 7 was specific
since vaccination with an irrelevant vaccinia virus failed to
protect (Fig . 1 A) .
Needfor Antigen to Maintain Antivirally Protective T Cell
Memory Demonstrated by Adoptive Transfer .
￿
Enhanced antiviral
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Figure 2 .
￿
Kinetics of CTLp frequencies of mice primed with various
doses of vacc-NP or vacc-GP. BALB/c (H-2a) mice were primed intrave
nously with 2 x 106 PFU vacc-GP (-*-), 2 x 10 2 ￿2 x 104
(-0-), or 2 x 106 (-&-) PFU of vacc-NP; 2 x 10 2 PFU of LCMV
(-A,), or 2 x 106 PFU of wild-type vaccinia virus
￿
After different
time intervals, the CTLp frequencies were determined in the spleens by
limiting dilution analysis (47, 48) in 7-d cultures in medium conditioned
with 10% conA supernatant . (A) Representative plot for the determina-
tion of CTLp frequencies on day 28 (see also Materials and Methods) .
(B) CTLp frequencies of the individual experimental groups are plotted .
protection may be explained by long-lived memory T cells
and/or by persisting antigen that maintains CTLs activated
at low levels . To evaluate the role of persistence of viral an-
tigen in T cell-mediated antivirally protective memory, adop-
tive transfer experiments were carried out (Table 2) . BALB/c
mice were immunized as indicated with 2 x 106 PFU of
vacc-NP, 2 x 106 PFU of vaccinia, or 10 2 PFU of LCMV .
At different time intervals after immunization, the spleens
were removed and 101 immune spleen cells were adoptively
transferred into syngeneic recipients (Table 2, Expt . 1) . The
recipients were infected intravenously with 200 PFU ofLCMV
on the day before (to enable the virus to replicate and induce
immunogenic antigen before cell transfer [27]) or on various
days after transfer. 4 d after infection, i.e., before the endoge-
nous antiviral response had developed, LCMV titers were mea-
sured in the recipients' spleens . Vacc-NP-immune spleen cells
from mice vaccinated 28 d previously reduced virus titers about
200-fold . 77-d immune cells reduced titers only by 10-fold
if recipient mice had been infected with LCMV on the day
before adoptive transfer (reduction by a factor of about 100
from 6 x 106 to 3 x 104 PFU/g spleen or by a factor of
about 10 from 2 x 106 to 2 x 105 PFU/g spleen on day
28 or 77, respectively) . The protective effect was markedly
decreased when recipient mice were challenged only on day
14 after transfer (about a 30-fold reduction from 2 x 106
to 9 x 104 vs . no reduction from 5 x 106 to 6 x 10 6
PFU/g spleen on day 28 or 77, respectively) . To test whether
spleen cells still contained replicating LCMV, an aliquot con-
taining about 107 spleen cells was injected in 30 /1 into the
footpads of a normal mouse (23, 28) . Typically, this detec-
tion assay is more sensitive than plaqueing ; it detects one
replicating unit ofLCMV (which is equivalent to about 2-5
PFU in 30 , .l of test material) . LCMV . initiates a local infec-
tion and induces a specific CTL response that causes the
footpad to dramatically swell after days 7-8 after infection
into the footpad (23, 26) . No footpad swelling was detected,
suggesting that less than 10 replicating LCMV particles perTable 2 .
￿
Antiviral Protection Mediated by Adoptively-transferred Spleen Cells: Influence of Type of Vaccine and of Time between
Adoptive Transfer and Challenge Infection
' BALB/c mice were immunized intravenously with 2 x 10 2 PFU LCMV-WE or 2 x 106 PFU vacc-NP . Immune cells were transferred after
the indicated times of vaccination of donors .
t Recipient mice were challenged with 2 x 10 2 PFU of LCMV-WE 1 d before, or the indicated days after transfer of immune cells intravenously .
Virus titers were determined 96 h after challenge infection in four to five individual mice per group . Mean ± SEM were determined .
S Level of infection was below the detection level of 2.7 logto PFU/g spleen .
108 spleen cells could have been transferred . The same test
did not reveal LCMV in any of the spleen cell populations.
In contrast to vacc-NP-immune cells, the 28-d LCMV
immune spleen cells conferred maximal antiviral protection
irrespective of the timewhen the challenge infection was given
on the day before (day -1) or +14 (Table 2, Expt. 1) . The
protective capacity of 77-dLCMVimmune spleen cells from
mice primed with 2 x 102 PFU of LCMV still provided
maximal antiviral protection ifrecipients were challenged with
LCMV on the day before, but importantly, not when chal-
lenged 14 d later. Thus 77 d after vaccination, LCMV and
vacc-NP-immune spleen cells "parked" for 14 d in a previ-
ously uninfected recipient completely failed to control virus
spread in the spleen . This strongly suggests that absence of
viral antigen in recipient mice resulted in loss ofthe antiviral
protective capacity of the transferred immune spleen cells .
The kinetics of loss of antiviral protection adoptively trans-
ferred by immune spleen cells was evaluated in greater detail
by varying the timing of the challenge infection and by trans-
ferring different numbers of cells (Table 2, Expt. 2) . After
adoptive transfer, 8 x 107 immune spleen cells (90 d im-
mune) were antivirally protective in hosts challenged 1 d later
(104-fold virus titer reduction from 8 x 10 6 in controls to
<6 x 10 2 PFU/g spleen), less so in hosts challenged 5 d
later (virus titer reduction by a factor of about 100 from 2
x 10 7 in controls to 3 x 105 PFU/g spleen in transfused
mice), and least active 7 d later (virus titer reduction by a
factor of 10 from 2 x 107 in controls to 2 x 106 PFU/g
spleen) . Eight times fewer cells, i.e., 107 LCMVimmune
spleen cells transferred excellent protective capacity to recipients
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challenged on day +1, but not to those challenged on day
+5 or day +7 after cell transfer (Table 2, Expt. 2) .
Discussion
In immunized mice, virus-specific CTL-mediated antiviral
protection declined with time after immunization . The type
of vaccine strongly influenced the duration ofthe protection .
If replication of the vaccine was limited, the duration of an-
tiviral protection depended upon the vaccine dose. This is
revealed in Fig. 1 B by decreased antiviral capacity of vacc-
GP-immunized mice as a function of immunizing dose and
time . The same phenomenon can be seen with the lowest
dose of vacc-NP (2 x 102), whereas the two higher doses
probably reflected antigen saturating conditions over the time
period tested . A similar correlation is found for a short time
period in the induction of LCMVNP-specific CTLp (Fig .
2 B) . Note, however, that CTLp frequencies of mice im-
munized with two higher doses of (2 x 104 or 2 x 106
PFU) vacc-GP were below detection level after more than
28 or 40 d . Thus, the antiviral protective potential in vivo
correlated with in vitro-measurable CTLp frequencies . The
small decline with time inCTLp frequencies of mice primed
with 2 x 104 or 2 x 106 vacc-NP (Fig . 2 B) did not
influence the measurable antiviral protection as assessed in
vivo by reduction of challenge virus titers . Maximal antiviral
protection was measured despite reduced CTLp frequencies
in recombinant vaccinia virus-primed mice when compared
with LCMV(2 x 102 PFU) primed mice that exhibited ten
times higher CTLp frequencies. This reflects the fact that
Expt .
Vaccination of
donor mice'
(No . cells
transferred)
Time after
vaccination
(days)
Challenge
- 1
Viral titers (log 10 PFU/g spleen)$
infection of recipient mice with respect to cell
+ 1 + 5 + 7
transfer on day
+14
1 Vacc (108 ) 28 6.8 ± 0 .1 ND ND ND 6.3 ± 0.3
Vacc-NP (108 ) 28 4.5 ± 0.1 ND ND ND 4.8 ± 0.1
LCMV (10 8 ) 28 <2.7s ND ND ND <2.7
Vacc (10 8 ) 77 6.2 ± 0.1 ND ND ND 6.7 ± 0.2
Vacc-NP (10 8 ) 77 5 .3 ± 0.1 ND ND ND 6.8 ± 0.2
LCMV (10 8 ) 77 <2.7 ND ND ND 6.7 ± 0.1
2 Vacc (8 x 10 7 ) 90 ND 6.9 ± 0.1 7.2 ± 0.2 7.2 ± 0.2 ND
LCMV (8 x 10 7 ) 90 ND <2.8 5.4 ± 0.2 6.3 ± 0.1 ND
LCMV (10 7 ) 90 ND 3.7 6.8 ± 0.3 6.8 ± 0.2 NDwith a given challenge dose ofLCMV, the scale of protec-
tion measurable by the virus titer reduction assay is limited
and that therefore experimental conditions cannot reveal the
existent, more substantial difference . However, the more po-
tent protection is revealed in the protection assay against lethal
LCM (compare 2 x 106 vacc-NP in 104 vs . 102 PFU LCMV-
challenged mice, Table 1) . The role of stimulating antigen
in the maintenance ofT cell memory was in addition shown
by adoptive transfer of memory CTLs. Efficiency of trans-
ferred protection depended upon the presence of stimulating
antigen in the recipients . If stimulating antigen was absent
or not provided within 7-14 d after cell transfer, protective
CTL memory declined rapidly to undetectable levels .
Thus, antigen dependence of antivirally protective immune
T cells was shown in the original host without disruption
of the structures of lymphoid organs and without forcing
memory T cells to recirculate and home under experimental
conditions, but was also shown in adoptive transfer experi-
ments. Taken together, our results show a remarkable corre-
lation between the existence of memory T cells as defined
by both in vitro (CTLp) and in vivo (antiviral protection)
assays. Apparently and understandably, the method of assaying
for protection against lethal LCM was less sensitive for de-
tecting T cell memory than for measuring virus titer reduc-
tion in spleens. Once a sufficient number of choriomeningeal
cells are infected, the immunopathology will be lethal . There-
fore, protectivememory against LCM needs to be very efficient
and quick to be protective . Besides the need for high levels
ofCTLp, thismay require relatively high levels of activation
as well . For assayingmemory in the spleen, the need for acti-
vationmay be less than formemoryT cells that have to recir-
culate to mediate effector functions in the choriomeninges
for LCM . Collectively, the results thus demonstrate that an-
tiviral protection in vivo reflects primed T cell populations
that are continuously driven and activated by persisting
antigen .
What are the limitations of the presented experiments and
of these interpretations? The presented and many earlier ex-
periments clearly show that the sensitivity of the readout
systems chosen obviously determines what generally is called
"CTL memory". Accordingly, CTL memory assessed as ca-
pacity to prevent LCM is relatively short-lived because the
assay is insensitive (see Table 1) . This is because LCMV in-
fects choriomeningeal cells rapidly and extensively without
CTL having a chance of eliminating virus promptly, except
when present and activated during, or briefly after, an acute
systemic infection . Paradoxically, and as has been shown in
a previous study (30) CTL memory may even be able to ac-
celerate LCMV under certain circumstances . The assessment
of antiviral protection by virus titer reduction is usually a
more sensitive parameter and obviously in most instances,
the most relevant one to validate vaccine-induced immuno-
logical memory. This parameter, but also CTLp determina-
tions in vitro, revealed rapid decline ofvacc-GP-inducedCTL
memory when antigen is limiting . Since LCMVGP codes
for a minor T cell epitope in H-2d mice, this finding is not
surprising . The primary cytotoxic T cell response in H-2d
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mice againstLCMVNP is at least 30-100 times stronger than
against LCMVGP (28) . Accordingly, the antivirally protec-
tive T cell response induced in H-2d mice by vacc-NP vs .
vacc-GP (Fig . 2) revealed a substantial difference of detect-
able CTLp in favor of NP.
One may argue that had the virus titer reduction been mea-
sured 1-2 d later even lower levels of CTL memory could
have been detected, but the interference of the recipients' own
immune response (even after low level irradiation) would com-
plicate the possible benefits ofthis prolonged protocol. Oper-
ationally, any lack of acceleration of virus elimination is bio-
logically meaningful and signals absence of protective T cell
memory and/or absence of activated T cells.
The findings obtained by adoptive transfer experiments are
limited by the uncertainties of whether transferred cells recir-
culate and home properly under the chosen experimental con-
ditions (8, 19, 20, 51) . However, since 28-d LCMV or vacc-
NP-immune spleen cells were able to confer high levels of
protection irrespective of whether recipients were infected
with LCMV on day -1 or day +14, there was no obvious
limitation to recirculation or homing by the recipient . Also,
this was not caused by transfer of virus, because we were
not able to detect LCMV or vacc-NP in the transferred spleen
cells, nor in the uninfected recipients above the stated detec-
tion levels of about 50-100 infectious units per spleen (or
5 x 102-103 PFU/g of spleen) . However, these findings
cannot exclude that infectious virus below this detection level
was transferred.
Collectively, the presented results suggested that protec-
tive memory cytotoxic T cells are T cell populations con-
tinuously activated by persisting antigen . Therefore, the pre-
viously reported modulations of various surface molecules
on naive or memory T cells may reflect physiologically acti-
vated T cells, rather than specially defined memory T cell
sets . Support for such an assumption may also be deduced
from recent work showing that modulation of CD45R is
not unidirectional but that so called memory T cells can re-
vert to the phenotype of naive T cells (52) . However, and
this is important in view ofprevious studies on memory, simple
lack of space (19) for adoptively transferred memory T cells
may not be invoked to explain the differing, strictly antigen-
dependent kinetics of adoptively transferred protectionshown
here .
Several earlier studies have analyzedCTL memory against
LCMV (31-35) . In these studies, as in the present one, CTL
mediated protection has been found to function for more than
1 yr, i .e ., for life. The role of antigen persistence was dis-
cussed but not evaluated as a limiting factor. This was difficult
to achieve in the models used, either because LCMV was not
completely cleared or because too much antigen had accu-
mulated to become limiting. Both the poorly replicating vac-
cinia recombinant viruses and adoptive transfer experiments
could overcome this problem in this study. Persistence of virus
as a possible source of continuously stimulating antigen has
been invoked to explain memory formany viruses including
herpes zoster or herpes simplex (53, 54) . For other viruses
to which CTL memory is very long-lived, such as influenza
Cytotoxic T Cell Memory to LCMV Is Governed by Persisting Antigenvirus, careful search has failed to reveal evidence for persis-
tence of viral genome (55). However, this does not exclude
the possibility that viralantigen may be stored on special cells
or specialized structures yet to be defined in a class I-presentable
form with a long half-life. Such a possibility may be sug-
gested by a recent study showing that class I-associated pep-
tides may have a half-life of >200-600 h (56). The results
showing that the in vivo antiviral protection specific for the
main T cell epitope is achieved with fewer PFU of vaccinia
recombinant virus and lasts for a considerably longer time
than found for the minor epitopes, may suggest that the
binding affinity of the peptide, together with its quantity,
may determine the crucial half-life of memory-promoting an-
tigen. Folliculardendritic cells have been shown to retain an-
tibody-antigen complexes to form antigen reservoirs for the
maintenance of B cell memory (11-13). Replicating antigen
(including persisting virus) driven into the class I-associated
antigen processing pathway may be a prerequisite of antivirally
protective activated T cells. It remains to be seen whether
other forms of antigen and antigen depot may be processed
in a class I-associated form to maintain both CTLp and pro-
tective memory, as may be suggested by experiments with
OVA (57, 58).
Besides very many examples to the contrary (1, 3, 10, 59-61)
there are nevertheless several studies that signal a relatively
short half-life for T cell memory, which is again crucially
dependent upon the sensitivity of the readout used. The im-
plication is that the more insensitive the test (e.g., as a result
of measurements under oversaturating conditions or in pa-
rameter ranges where changes have no overt effect) the more
long-lasting T cell memory will appear. For example, studies
on T cell protection against Listeria (18) or T h cells specific
for bovine gamma globulin (15) for sheep RBC (16), for cross-
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